PTLA Portola Pharmaceuticals Inc.

18.85
-0.26  -1%
Previous Close 19.11
Open 18.74
Price To Book 7.6
Market Cap 1252281390
Shares 66,434,026
Volume 1,057,215
Short Ratio
Av. Daily Volume 1,575,611

SEC filingsSee all SEC filings

  1. 8-K - Current report 181227830
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 181166911
  3. 8-K - Current report 181166438
  4. SC 13G - Statement of acquisition of beneficial ownership by individuals 181128300
  5. 8-K - Current report 181120608

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

FDA Approval noted June 23, 2017.
Bevyxxa (betrixaban)
Venous thromboembolism (VTE) Prevention
Phase 2 updated data due at ASH December 2018 noted ORR 34%; 27% CR and in the PTCL cohort ORR 26%; 7% CR.
Cerdulatinib (PRT2070)
Refractory non-Hodgkin lymphoma and chronic lymphocytic leukemia - cancer
Approval announced May 3, 2018. PDUFA date December 31, 2018 for Prior Approval Supplement (PAS).
Andexxa
Factor Xa inhibitor reversal agent

Latest News

  1. Here's Why Portola Pharmaceuticals Fell 11% Today
  2. Is Portola Pharmaceuticals Inc (PTLA) A Good Stock To Buy?
  3. Portola (PTLA) Down as CHMP Defers Review Date for Ondexxya
  4. Why Portola Pharmaceuticals’ Stock Price Is Plummeting Today
  5. Portola Pharma shares slide 6% on news of delay in EU review of treatment for bleeding
  6. CHMP Extends Review Period for Portola Pharmaceuticals’ Ondexxya™ (andexanet alfa)
  7. Recent Analysis Shows Portola Pharmaceuticals, Xenia Hotels & Resorts, WestRock, Newtek Business Services, The ExOne, and VMware Market Influences — Renewed Outlook, Key Drivers of Growth
  8. Updated Interim Results from Ongoing Phase 2a Study of Portola Pharmaceuticals’ Oral Syk/JAK Inhibitor Cerdulatinib Continues to Demonstrate Clinical Responses in Heavily Pre-Treated T-Cell Malignancies
  9. See what the IHS Markit Score report has to say about Portola Pharmaceuticals Inc.
  10. Portola Pharmaceuticals Stock Rose after Its Q3 2018 Results
  11. Here's What Portola Pharmaceuticals Is Saying About Its Future
  12. Today's Research Reports on Trending Tickers: Portola Pharmaceuticals and Global Blood Therapeutics
  13. Edited Transcript of PTLA earnings conference call or presentation 7-Nov-18 9:30pm GMT
  14. Portola Pharmaceuticals (PTLA) Reports Q3 Loss, Tops Revenue Estimates
  15. Portola Pharmaceuticals: 3Q Earnings Snapshot
  16. Portola Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update
  17. Portola Pharmaceuticals to Participate in Two Upcoming Investor Conferences
  18. Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  19. Portola Pharmaceuticals to Present New Interim Phase 2 Results for Cerdulatinib During an Oral Session at the 60th American Society of Hematology (ASH) Annual Meeting

SEC Filings

  1. 8-K - Current report 181227830
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 181166911
  3. 8-K - Current report 181166438
  4. SC 13G - Statement of acquisition of beneficial ownership by individuals 181128300
  5. 8-K - Current report 181120608
  6. 8-K - Current report 181078735
  7. 8-K - Current report 181058944
  8. 10-Q - Quarterly report [Sections 13 or 15(d)] 181004945
  9. 8-K - Current report 181003510
  10. 8-K - Current report 18892309